mal amido (ch2cooh)2

Mal-amido-(CH2COOH)2, also known as compound 7a, is an intermediate compound that contains maleimidoethyl for use in hydrophilic ADC linker synthesis[1].

5-Ethynyl-2'-deoxyuridine (EdU) is a nucleoside analog of thymidine used to monitor de novo DNA synthesis through click chemistry and serves as an alkyl chain-based PROTAC linker for synthesizing PROTACs.

1,2-Bis(2-iodoethoxy)ethane is a PEG-based PROTAC linker used in the synthesis of MT802 and SJF620, which are potent PROTAC BTK degraders with DC50s of 1 nM and 7.9 nM, respectively [1].

2-Phthalimidehydroxy-acetic acid is an alkyl chain-based PROTAC linker utilized in PROTAC synthesis.

Mal-amido-PEG7-acid (Mal-NH-PEG7-COOH) is a PEG-based PROTAC linker that can be used to synthesize PROTACs.

dMCL1-2 is a potent and selective myeloid leukemia 1 (MCL1) degrading agent based on PROTAC, binding to MCL1 with a KD of 30 nM and activating the apoptosis mechanism by degrading MCL1.

PROTAC ERRα ligand 2 is an inverse agonist for the estrogen-related receptor α (ERRα) with an IC50 of 5.67 nM.

TSPO ligand-2 (Carbonic acid) is a ligand of AUTAC1 which contains a p-fluorobenzylguanine and a Fumagillol moiety.

Hydroxy-PEG4-(CH2)2-Boc is an uncleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADCs) and can also be employed in the synthesis of PROTAC.

Mal-amido-PEG2-Val-Cit-PAB-PNP is a cleavable, 2-unit polyethylene glycol (PEG) based ADC linker used in the construction of antibody-drug conjugates (ADCs) [1].

PROTAC MDM2 Degrader-2, designed using PROTAC technology, functions as a MDM2 degrader. It consists of a highly potent MDM2 inhibitor, a linker, and the MDM2 ligand for E3 ubiquitin ligase, facilitating the degradation of MDM2[1].

4-Methyl-4-(pyridin-2-yldisulfanyl)pentanoic acid is a cleavable linker compound used in the synthesis of antibody-drug conjugates (ADCs) [1].

Biotinyl-NH-PEG3-C3-amido-C3-COOH (DIPEA) is a polyethylene glycol (PEG)-based PROTAC linker used in the synthesis of proteolysis targeting chimeras (PROTACs).

PROTAC BRD4 Ligand-2 Hydrochloride serves as a ligand targeting the BRD4 protein, specifically designed for use with PROTAC CFT-2718.

Pomalidomide-amido-C3-COOH is a conjugate compound synthesized as an E3 ligase ligand-linker, combining a cereblon ligand derived from Pomalidomide with a linker, both utilized in PROTAC technology.

Mal-amido-PEG6-acid is a PEG-based linker for PROTACs that joins two essential ligands, crucial for forming PROTAC molecules, and enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

PROTAC BET-binding moiety 2 is an inhibitor of the BET bromodomain.

cIAP1 Ligand-Linker Conjugates 2 is a chemical compound that combines an IAP ligand for the E3 ubiquitin ligase with a PROTAC linker. This compound is particularly useful in the design of SNIPERs [1].

PROTAC ERRα Degrader-2 is a compound consisting of an MDM2 ligand binding group, a linker, and an estrogen-related receptor alpha (ERRα) binding group. This compound is designed to specifically degrade estrogen-related receptor alpha (ERRα), acting as an ERRα degrader[1].

SNIPER(TACC3)-2 targets TACC3 protein degradation via the ubiquitin-proteasome pathway. It induces cancer cell death.

PROTAC Bcl-xL degrader-2, based on von Hippel-Lindau ligand, is a potent degrader of Bcl-xL (a Bcl-2 family member), demonstrating an IC 50 of 0.6 nM.

PROTAC VEGFR-2 Degrader-1 (PROTAC-1), a specific degrader of PROTAC VEGFR-2, demonstrates minimal inhibition of VEGFR-2 (IC50 > 1 μM) and exhibits low anti-proliferative effects on EA.hy926 cells (IC50 > 100 μM) [1].

PROTAC VEGFR-2 degrader-2 (PROTAC-4), a specific degrader of VEGFR-2, demonstrates minimal inhibition of VEGFR-2 (IC50 > 1 μM) and low anti-proliferative activity towards EA.hy926 cells (IC50 > 100 μM) [1].

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized E3 ligase ligand-linker, incorporating a cereblon ligand based on Thalidomide and a 3-unit PEG linker, specifically designed for PROTAC technology applications.

(R)-Azetidine-2-carboxylic acid, with catalog number T66331 and CAS number 7729-30-8, is a valuable organic compound for life sciences research.

Mal-amido-PEG8-C2-acid (US2018339985, example 142) is a noncleavable linker for antibody-drug conjugates (ADCs) [1].

6-O-2-Propyn-1-yl-D-galactose functions as an irreversible glycolinker, facilitating the attachment of cytotoxic drugs for applications in antibody-drug conjugation (ADC).

Mal-amido-PEG9-NHS ester is a PEG-based linker for PROTACs, joining two essential ligands crucial for forming PROTAC molecules, and enabling selective protein degradation by leveraging the ubiquitin-proteasome system [within cells].

SLF-amido-C2-COOH is a synthetic ligand for FKBP (SLF), and can be used in the synthesis of PROTACs.

Mal-amido-PEG2-TFP ester is a polyethylene glycol (PEG)-based linker featuring amide functionality and a trifluorophenyl (TFP) ester group, used in PROTAC synthesis as a PEG-based PROTAC linker [1].

Bis (2-bromoethyl) ether, an alkyl chain-derived PROTAC linker, facilitates the synthesis of PROTACs.

Mal-amido-PEG8-val-gly-PAB-OH, an eight-unit PEG cleavable linker, is frequently employed in the synthesis of antibody-drug conjugates (ADCs)[1].

Bis-Tos-(2-hydroxyethyl disulfide) is a cleavable linker used in the synthesis of antibody-drug conjugates (ADCs) [1].

PEG6-(CH2CO2H)2 is a symmetric PEG PROTAC linker.

DBCO-(PEG2-Val-Cit-PAB)2 is a dual-cleavable linker used in antibody-drug conjugates (ADCs).

GID4 Ligand 2 (compound 67) is a selective binder for GID4 with an IC50 of 18.9 μM and a Kd of 17 μM, and can be used for the synthesis of PROTACs [1].

Mal-amido-PEG9-NH-Boc is a PEG-based linker for PROTACs that connects two vital ligands, essential for forming PROTAC molecules, and enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

(2-Pyridyldithio)-PEG4-alcohol, a PEG-based PROTAC linker, is used for the synthesis of PROTACs[1].

PROTAC EGFR degrader 2 is a potent compound with an IC50 of 4.0 nM, demonstrating strong antiproliferative activity, and a DC50 of 36.51 nM, indicating robust EGFR degradation activity. It is suitable for synthesizing nitroreductase (NTR)-responsive PROTACs [1].

YX-2-107 is a selective and potent CDK6-degrading PROTAC with an IC50 value of 4.4 nM.YX-2-107 inhibits RB phosphorylation and FOXM1 expression in vitro, and inhibits the development of Ph+ ALL in rats.YX-2-107 can be used for the prophylaxis and treatment of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). YX-2-107 can be used for the prevention and treatment of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

PROTAC STAT3 degrader-2 is a selective and effective PROTAC degrader of the STAT3 protein, exhibiting a DC50 of 3.54 μM in Molm-16 cells. It holds potential for cancer research [1].

RIPK2-IN-2 (example 25) is a RIP2 kinase PROTAC inhibitor that effectively blocks RIP2-dependent pro-inflammatory signaling and regulates RIP2 kinase activity in autoinflammatory diseases [1].

Mal-amido-PEG2-C2-acid is a PEG-based linker for PROTACs, facilitating the conjugation of two essential ligands to form PROTAC molecules. This linker enables selective protein degradation by utilizing the ubiquitin-proteasome system within cells.

Mal-amido-PEG12-TFP ester is a polyethylene glycol (PEG)-based linker used in the synthesis of proteolysis targeting chimeras (PROTACs)[1].

Mal-amido-PEG3-NHS ester is a PEG-based linker for PROTACs that joins two essential ligands, which are crucial for forming PROTAC molecules. This linker facilitates selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

NJH-2-030 is a covalent recruiting compound utilized in targeted protein degradation applications for FEM1B.

PROTAC CRABP-II Degrader-2 is a potent cIAp1-based degrader of cellular retinoic acid binding protein (CRABP-II).

PROTAC PTPN2 degrader-2 (example 187B) TFA is a potent Protein Tyrosine Phosphatase Non-receptor Type 2 (PTPN2) degrader with potential applications in cancer and metabolic disease research [1].